Table 2.

Patient characteristics

CharacteristicStratum A, not on EIAED* (n = 15)Stratum B, on EIAED (n = 19)All patients (n = 34)
Age (y)
    Median56.348.849.9
    Range32.8-76.832.9-65.832.8-76.8
Sex
    Male7 (47%)16 (84%)23 (68%)
    Female8 (53%)3 (16%)11 (32%)
Histology
    GBM/GS12 (80%)17 (87%)29 (85%)
    AA3 (20%)2 (11%)5 (15%)
KPS
    90-1009 (60%)13 (68%)22 (65%)
    70-806 (40%)6 (32%)12 (35%)
Prior XRT15 (100%)19 (100%)34 (100%)
Prior chemotherapy15 (100%)19 (100%)34 (100%)
No. prior chemotherapy agents
    14 (27%)8 (42%)12 (35%)
    24 (27%)5 (26%)9 (26%)
    ≥37 (47%)6 (32%)13 (38%)
Median222
No. prior progressions
    14 (27%)9 (47%)13 (38%)
    28 (54%)7 (37%)15 (44%)
    33 (20%)3 (16%)6 (18%)
Median222
Median time from diagnosis to initiation (wk)30.7 (range, 7.3-179.6)28.9 (range, 10.9-248.0)29.8 (range, 7.3-248.0)
  • Abbreviations: GBM, glioblastoma multiforme; GS, gliosarcoma; AA, anaplastic astrocytoma; KPS, Karnofsky performance status; XRT, X-ray therapy.

  • * EIAEDs: phenytoin, carbamazepine, phenobarbitol, oxcarbazepine, and primidone.